Nanotein

Nanotein is a private, early-stage biotech founded in 2021 and based in Cambridge, USA, focusing on the proteomics and antibodies sectors within cell therapy manufacturing. The company's core innovation is the NanoSpark platform, a soluble, protein-based reagent technology designed to outperform traditional methods by enhancing the expansion and stemness of therapeutic T cells. With initial products for CAR-T and NK cell expansion already launched and a strategic partnership with Sartorius Stedim Biotech, Nanotein is positioned to address critical bottlenecks in the scalable production of next-generation cell therapies. The company is currently pre-revenue, operating in a commercial/development hybrid stage by selling research-use reagents while paving the path for clinical adoption.

NanoSpark® platform: a proprietary engineered protein-nanoparticle scaffold that can be conjugated with multiple antibodies/cytokines to geometrically orient them for optimal immune cell receptor clustering, activation, and expansion.

Nanotein competes with established life science tools companies offering T-cell activation products (e.g., Thermo Fisher's Dynabeads, Miltenyi Biotec's TransAct) and other startups developing novel activation technologies. Its differentiation lies in its soluble, protein-based nanoparticle approach aimed at superior cell stemness and expansion yields.